Clinical trials: Recurrent Herpes Simplex
Herpes Labialis
Comparative Safety and Efficacy of Two Antiviral Treatments in the Treatment of Recurrent Herpes Simplex Labialis
To compare safety and efficacy of Perrigo's antiviral drug product compared to an FDA approved antiviral drug product in the treatment of cold sores.
- Trial name
- NCT02265913
- Testing
- Acyclovir 5 percent (Perrigo), Acyclovir 5 percent (Reference)
- Where
- United States
- Volunteers
- 4,076 people
- Sponsor
- Padagis LLC
Herpes Genitalis
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A study of ASP2151 in subjects with recurrent outbreaks of genital herpes.
- Trial name
- NCT00486200
- Testing
- ASP2151, valacyclovir
- Where
- 25 sites in United States
- Volunteers
- 695 people
- Sponsor
- Astellas Pharma Inc
Recurrent Herpes Labialis
A Study to Evaluate the Safety and Efficacy of Single Day or Single Dose Famciclovir for the Treatment of Recurrent Herpes Labialis
The study is designed to assess the efficacy and safety of patient-initiated therapy with famciclovir 1500 mg o.d. or 750 mg b.i.d. for one day treatment in adult men and women with recurrent herpes labialis
- Trial name
- NCT00248144
- Testing
- Famciclovir
- Sponsor
- Novartis
Herpes Simplex, HIV Infections
A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients
To evaluate the safety and efficacy of oral valacyclovir hydrochloride (256U87) vs. acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients (CD4 greater than or equal to 100).
- Trial name
- NCT00002000
- Testing
- Valacyclovir hydrochloride, Acyclovir
- Where
- 22 sites in United States
- Sponsor
- Glaxo Wellcome
Herpes Labialis
NB-001 Treatment of Recurrent Herpes Labialis
This is a study to test the hypothesis that time to healing of a cold sore will be lower in the active treatment arm of the study when compared to the vehicle (placebo).
- Trial name
- NCT01695187
- Testing
- NB-001 (0.3%)
- Where
- 12 sites in United States
- Volunteers
- 362 people
- Sponsor
- NanoBio Corporation
Recurrent Herpes Labialis
A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS)
The purpose of this study is to demonstrate the safety and efficacy of NB-001 in subjects with recurrent herpes labialis (RHL).
- Trial name
- SHaRCS (NCT01324466)
- Testing
- NB-001, Vehicle
- Where
- 35 sites in United States
- Volunteers
- 847 people, healthy volunteers welcome
- Sponsor
- NanoBio Corporation
Herpes Labialis
Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes
Randomized, double-blind, multi-center, three arm parallel group, comparative trial to assess pritelivir ointment safety and efficacy, ie, proportion of subjects with non-ulcerative lesions, in adult subjects with recurrent…
- Trial name
- LipP1 (NCT02871492)
- Testing
- Pritelivir 5% w/w ointment, Zovirax® cream
- Where
- 10 sites in United States
- Volunteers
- 362 people
- Sponsor
- AiCuris Anti-infective Cures AG
Herpes Labialis
Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis
Purpose of this study is to determine the safety and efficacy of topical applications of NB-001 as compared to placebo for the treatment of recurrent herpes labialis.
- Trial name
- NCT00453401
- Testing
- NB-001
- Where
- 28 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- NanoBio Corporation
Genital Herpes
Patient-initiated Episodic Treatment of Recurrent Genital Herpes in Black Patients
This study will evaluate the safety and efficacy of single-day famciclovir episodic treatment in Black patients with recurrent genital herpes
- Trial name
- NCT00477334
- Testing
- Famciclovir
- Where
- 43 sites in United States, South Africa
- Volunteers
- 463 people
- Sponsor
- Novartis
Herpes Simplex
A Study on the Reactogenicity, Safety, Immune Response, and Efficacy of a Targeted Immunotherapy Against HSV in Healthy Participants Aged 18-40 Years or in Participants Aged 18-60 Years With Recurrent Genital Herpes
The purpose of this first-time-in-human (FTiH) study is to evaluate the reactogenicity, safety, immune response, and efficacy of an investigational herpes simplex virus (HSV)-targeted immunotherapy (TI).
- Trial name
- NCT05298254
- Testing
- Non-adjuvanted HSV formulation 1, Non-adjuvanted HSV formulation 2, Non-adjuvanted HSV formulation 3
- Where
- 30 sites in United States, Australia and 6 more
- Volunteers
- 505 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Genitalis
An Epidemiological Study to Assess Performance of Using Healthcare Tools to Understand Genital Herpes Simplex Virus-2 (HSV-2) in Patients ≥ 18 Years of Age in the United States and Europe.
The aim of this study is to assess performance of using healthcare tools to understand genital Herpes Simplex Virus-2 (HSV-2) in patients ≥ 18 years of age in the United States and Europe.
- Trial name
- NCT04950712
- Testing
- Blood sampling, Anogenital lesion swab collection
- Where
- 51 sites in United States, Finland and 4 more
- Volunteers
- 537 people
- Sponsor
- GlaxoSmithKline
HSV-2
Safety Study of HSV2 DNA Vaccine to Treat Patients With Recurrent Genital Herpes Caused by HSV-2
The purpose of this study is to evaluate how well the vaccine is tolerated at sites where administrations are given and any effects it may have on subjects' wellbeing.
- Trial name
- NCT00274300
- Testing
- pPJV7630 administered by PMED
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- PowderMed
Recurrent Herpes Labialis
An Open Label Study to Evaluate the Safety and Efficacy of BOR15001L7 for the Treatment of Cold Sores in Patients With Recurrent Herpes Labialis
BOR15001L7 is a natural product. The primary objective of this study is to demonstrate its non-inferiority to docosanol 10% based on the healing time of cold sores in patients with recurrent herpes labialis.
- Trial name
- NCT03977792
- Testing
- BOR15001L7, Docosanol Cream 10%
- Volunteers
- 164 people
- Sponsor
- Laboratoire Boreaderme Inc.
Glioma, Astrocytoma
Safety and Effectiveness Study of G207, a Tumor-Killing Virus, in Patients With Recurrent Brain Cancer
This clinical trial will study the safety and effectiveness of an engineered herpes virus, G207, administered directly into the brain of patients with recurrent brain cancer.
- Conditions
- Glioma, Astrocytoma, Glioblastoma
- Trial name
- NCT00028158
- Testing
- G207, an oncolytic virus
- Volunteers
- 65 people
- Sponsor
- MediGene
Herpes Labialis
Iontophoretic Application of Acyclovir Gel to Treat Cold Sores
Currently approved drugs for the treatment of herpes labialis (cold sores) exhibit low levels of efficacy due to the limited ability of the drugs to penetrate the skin to the sites where the herpes virus is replicating.
- Trial name
- NCT00469300
- Testing
- Iontophoretic delivery of acyclovir
- Where
- 13 sites in United States
- Volunteers
- 810 people
- Sponsor
- Transport Pharmaceuticals
Herpes Simplex Type 2
Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital Herpes
The purpose of this study is to evaluate the effect of recombinant human heat shock protein 70-polyvalent peptide complex (HerpV) vaccine administration on recurring episodes of genital herpes by evaluating viral shedding before…
- Trial name
- NCT01687595
- Testing
- HerpV and QS-21
- Where
- 5 sites in United States
- Volunteers
- 80 people
- Sponsor
- Agenus Inc.
Recurrent Genital Herpes
Efficacy and Safety of Oral Famciclovir in Patients With Active Recurrent Genital Herpes
This is a phase III, multicenter, randomized, double-blind, parallel-group study to compare the efficacy and safety of a two-day treatment with famciclovir (500 mg loading dose followed by 250 mg 12-hourly) to standard five-day…
- Trial name
- NCT00171990
- Testing
- Famciclovir
- Where
- Australia
- Volunteers
- 1,461 people
- Sponsor
- Novartis
Herpes Labialis
VALTREX(Valacyclovir) Once Daily for Viral Shedding In Subjects Newly Diagnosed With HSV-2
Eligible subjects will be randomized to receive VALTREX 1g or placebo once daily for 60 days in a two-way crossover study with a washout period of 7 days in between.
- Trial name
- NCT00306293
- Testing
- valacyclovir
- Where
- 18 sites in United States
- Volunteers
- 70 people
- Sponsor
- GlaxoSmithKline
Recurrent Herpes Simplex Labialis
A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis
Demonstrate the safety and efficacy of NB-001 in subjects with recurrent herpes labialis (RHL).
- Trial name
- SHaRCS (NCT01321359)
- Testing
- Vehicle versus NB-001
- Where
- 35 sites in United States
- Volunteers
- 907 people, healthy volunteers welcome
- Sponsor
- NanoBio Corporation
Genital Herpes Simplex Type 2
A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions
This exploratory trial will have three parts. Part A is a dose escalation part, Part B is an expanded safety and dose evaluation part, and Part C is a safety and immunogenicity evaluation part in individuals with recurrent HSV-2…
- Trial name
- NCT05432583
- Testing
- BNT163
- Where
- 6 sites in United States
- Volunteers
- 318 people, healthy volunteers welcome
- Sponsor
- BioNTech SE